MiMedx Group, Inc. (MDXG) Cash Flow Statement

The ratio of operating cash flow to net income has ranged widely, reaching 2.53 in 2024Q4 and turning negative in 2026Q1 and 2026Q3 when net income was also negative, which makes the ratio analytically unreliable in loss periods. Positive conversion in 2024 and 2025 suggests that reported earnings were backed by cash at that time, but the rapid reversal into 2026 warrants further investigation into whether working capital timing or collection patterns drove the swing. Investors should monitor whether conversion stabilizes once the earnings base normalizes.

The FCF trajectory shows a peak-to-trough compression that mirrors the revenue decline visible in the income statement, suggesting that free cash generation is closely tied to top-line demand. The 2026Q3 rebound to an 8.3% margin is encouraging but follows a single quarter of substantial working capital inflow, which may not be repeatable. Sustained positive FCF will need to be confirmed over additional quarters before it can be treated as a durable trend.

Large swings in working capital in both directions suggest that a significant share of quarterly operating cash flow reflects timing rather than underlying earnings power. The $15.4M inflow in 2026Q1 occurred alongside a net loss, which implies that cash was released from balance sheet accounts rather than generated by operations. This pattern warrants further investigation into receivable collection and inventory management.

Capital spending is light relative to revenue, which points to an asset-light model and means free cash flow is not materially eroded by reinvestment needs. Depreciation and amortization exceeding CapEx in most quarters suggests that the asset base is being consumed faster than it is replaced, though the gap is modest in absolute terms. Investors should monitor whether low reinvestment is sustainable if revenue recovery requires capacity or product investment.